<DOC>
	<DOCNO>NCT00172809</DOCNO>
	<brief_summary>The treatment response conventional interferon alpha alone patient end stage renal disease chronic hepatitis C 33-39 % . However , drop-out rate 17-29.6 % . Pegylated interferon alpha , newly develop form interferon superior pharmacokinetic profile , use treatment patient . We expect well treatment response treat peginterferon alpha conventional interferon . In addition , also observe safety two drug study . The goal study compare efficacy safety two different treatment regimens patient chronic hepatitis C end stage renal disease .</brief_summary>
	<brief_title>Interferon Treatment Patients With Chronic Hepatitis C End Stage Renal Disease</brief_title>
	<detailed_description>Chronic hepatitis C virus ( HCV ) infection common among patient end stage renal disease ( ESRD ) , report prevalence range 8 20 % dialysis patient develop world . In Taiwan , estimate prevalence HCV infection patient ESRD maintain hemodialysis range 20 24.7 % . Although study provide mild moderate disease activity high proportion normal alanine aminotransferase ( ALT ) level , frequency bridge hepatic fibrosis cirrhosis range 5 32 % . Several study show chronic hepatitis C adversely affect survival patient ESRD . After renal transplantation , recipient HCV increase risk liver-related mortality morbidity compare without HCV . Therefore , eradication HCV improve clinical outcome dialysis patient well patient await renal transplantation . Combined interferon ribavirin standard therapy HCV-infected patient normal renal function . However , ribavirin , clear kidney , may cause severe hemolytic anemia dangerous dialysis patient . Two recent meta-analyses show sustained virological response ( SVR ) 39 % 33 % ; drop-out rate 17 % 29.6 % HCV-infected dialysis patient treat interferon-alpha 3 MU thrice weekly vary duration . The response drop-out rate higher report HCV-infected patient normal renal function ( SVR 7-16 % interferon-alpha 3 MU thrice weekly 24 week ; drop-out rate 5-9 % ) due low interferon clearance rate . Peginterferon alpha-2a ( 40KD ) modify form interferon alpha-2a consist branch polyethylene glycol ( PEG ) chain covalently bound interferon alpha-2a . A good response peginterferon alpha-2a interferon alpha-2a demonstrate HCV-infected patient normal renal function , either combine ribavirin , due superior pharmacokinetic profile . The clearance peginterferon alpha-2a ESRD patient 30-40 % low healthy subject . A similarly pharmacokinetic profile peginterferon alpha-2a observe 135 μg weekly dialysis patient compare 180μg weekly patient normal renal function . We expect peginterferon alpha-2a superior interferon alpha-2a achieving increase SVR decrease drop-out rate dialysis patient . The goal study compare efficacy safety two different treatment regimens patient chronic hepatitis C end stage renal disease .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age 18 65 year old Creatinine clearance ( Ccr ) &lt; 10 ml/min/1.73 m2 Receiving regular hemodialysis AntiHCV ( Abbott HCV EIA 2.0 , Abbott Diagnostic , Chicago , IL ) positive &gt; 6 month Detectable serum HCVRNA ( Cobas Amplicor HCV Monitor v2.0 , Roche Molecular Systems , Pleasanton , CA ) dynamic range 600~ &lt; 500,000 IU/ml Neutropenia ( neutrophil count , &lt; 1,500/mm3 ) Thrombocytopenia ( platelet &lt; 90,000/ mm3 ) Coinfection HBV HIV Chronic alcohol abuse ( daily consumption &gt; 20 g/day ) Decompensated liver disease ( Child classification B C ) Neoplastic disease An organ transplant Immunosuppressive therapy Poorly control autoimmune disease , pulmonary disease , cardiac disease , psychiatric disease , neurological disease , diabetes mellitus Evidence drug abuse Unwilling contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>End stage renal disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Interferon</keyword>
	<keyword>Pegylated interferon</keyword>
</DOC>